My husband's tumor is showing progression. His NO (Kaiser) has a study NCT03149003 "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)" All I know is that it's a cancer peptide vaccine. There's a blood test to confirm presence of HLA.
Does anyone know anything about this agent?
I'm looking at other possible trials to see if there's anything that might be a better fit, or that would keep him bevacizumab naive since using bev would further restrict his trial eligibility (multifocal and inoperable means many trials are ruled out). We are in southern California and I'd prefer not to travel far unless it's for an exceptional option. He unfortunately did not qualify for City of Hope's CAR-T trial.
Thanks for any suggestions or insight.
Participants in this trial are randomized into two arms: one arm gets Avastin only, and the other arm gets Avastin + DSP-7888. So that is one strike against the trial. But at least it's open-label, so there's no placebo.
ReplyDeleteDSP-7888 is a vaccine targeting WT1. WT1 is an interesting target in GBM, and one study with a different WT1 vaccine showed quite good outcomes:
https://www.ncbi.nlm.nih.gov/pubmed/25772149
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Another trial you could look into recruiting in Los Angeles (Cedars Sinai) is:
https://clinicaltrials.gov/ct2/show/NCT02026271 (Ad-RTS-hIL-12 With Veledimex)
The BEV +/- DSP-7888 is actually a decent trial, but it's a roll of the dice which arm he would be placed in.
Thanks Stephen. Waiting to hear from the Cedars Sinai folks. That trial does not require being naive on bevacizumab, just a four week washout, so it theoretically could be pursued after the DSP-7888.
ReplyDeleteAlso a call in to John Wayne about https://clinicaltrials.gov/ct2/show/study/NCT02330562 (Marizomab).